Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks

A. Marchesi, I. Tarissi De Jacobis, D. Rigante, A. Rimini, W. Malorni, G. Corsello, G. Bossi, S. Buonuomo, F. Cardinale, E. Cortis, F. De Benedetti, A. De Zorzi, M. Duse, D. Del Principe, R.M. Dellepiane, L. D'Isanto, M. El Hachem, S. Esposito, F. Falcini, U. Giordano & 13 others M.C. Maggio, S. Mannarino, G. Marseglia, S. Martino, G. Marucci, R. Massaro, C. Pescosolido, D. Pietraforte, M.C. Pietrogrande, P. Salice, A. Secinaro, E. Straface, A. Villani

Research output: Contribution to journalArticle

Abstract

This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications. © 2018 The Author(s).
Original languageEnglish
JournalItalian Journal of Pediatrics
Volume44
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Mucocutaneous Lymph Node Syndrome
Life Style
Guidelines
Pediatrics
Therapeutics

Keywords

  • anakinra
  • apixaban
  • canakinumab
  • clopidogrel
  • dabigatran
  • fondaparinux
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • infliximab
  • low molecular weight heparin
  • methylprednisolone
  • prednisone
  • rivaroxaban
  • tissue plasminogen activator
  • warfarin
  • immunoglobulin
  • nonsteroid antiinflammatory agent, abdominal pain
  • adrenal cortex insufficiency
  • anaphylaxis
  • angioneurotic edema
  • arthralgia
  • atherosclerosis
  • bleeding
  • bradycardia
  • bronchospasm
  • cardiovascular disease
  • cardiovascular risk
  • cataract
  • chorioretinopathy
  • congestive heart failure
  • coronary artery aneurysm
  • coronary artery thrombosis
  • diabetes mellitus
  • diarrhea
  • digestive system perforation
  • disease classification
  • disease severity
  • dizziness
  • drug efficacy
  • drug mechanism
  • dysphagia
  • eosinophilia
  • erythema
  • face edema
  • fatigue
  • fitness
  • follow up
  • gastrointestinal hemorrhage
  • gastrointestinal symptom
  • glaucoma
  • hand edema
  • headache
  • heart arrhythmia
  • heart surgery
  • heart transplantation
  • human
  • hyperglycemia
  • hypersensitivity
  • hypertension
  • hypertransaminasemia
  • hypocalcemia
  • hypotension
  • hypothermia
  • hypovolemic shock
  • infection
  • influenza
  • information dissemination
  • intracranial hypertension
  • invasive procedure
  • lifestyle
  • liver failure
  • malaise
  • mucocutaneous lymph node syndrome
  • myalgia
  • myopathy
  • nausea
  • neutropenia
  • osteoporosis
  • pain
  • pancreatitis
  • pediatrician
  • Perthes disease
  • physician
  • plasmapheresis
  • pneumonia
  • practice guideline
  • pruritus
  • rash
  • Review
  • rhinitis
  • rhinopharyngitis
  • seizure
  • shock
  • sinusitis
  • skin bruising
  • thrombocytopenia
  • thrombosis
  • thrombotic thrombocytopenic purpura
  • treatment contraindication
  • treatment indication
  • upper respiratory tract infection
  • urticaria
  • vomiting
  • child
  • coronary artery disease
  • drug resistance
  • female
  • male
  • medical society
  • pediatrics
  • preschool child
  • risk assessment
  • severity of illness index, Anti-Inflammatory Agents, Non-Steroidal
  • Cardiovascular Diseases
  • Child
  • Child, Preschool
  • Coronary Artery Disease
  • Drug Resistance
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous
  • Male
  • Mucocutaneous Lymph Node Syndrome
  • Pediatrics
  • Practice Guidelines as Topic
  • Risk Assessment
  • Severity of Illness Index
  • Societies, Medical

Cite this

Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. / Marchesi, A.; Tarissi De Jacobis, I.; Rigante, D.; Rimini, A.; Malorni, W.; Corsello, G.; Bossi, G.; Buonuomo, S.; Cardinale, F.; Cortis, E.; De Benedetti, F.; De Zorzi, A.; Duse, M.; Del Principe, D.; Dellepiane, R.M.; D'Isanto, L.; El Hachem, M.; Esposito, S.; Falcini, F.; Giordano, U.; Maggio, M.C.; Mannarino, S.; Marseglia, G.; Martino, S.; Marucci, G.; Massaro, R.; Pescosolido, C.; Pietraforte, D.; Pietrogrande, M.C.; Salice, P.; Secinaro, A.; Straface, E.; Villani, A.

In: Italian Journal of Pediatrics, Vol. 44, No. 1, 2018.

Research output: Contribution to journalArticle

Marchesi, A, Tarissi De Jacobis, I, Rigante, D, Rimini, A, Malorni, W, Corsello, G, Bossi, G, Buonuomo, S, Cardinale, F, Cortis, E, De Benedetti, F, De Zorzi, A, Duse, M, Del Principe, D, Dellepiane, RM, D'Isanto, L, El Hachem, M, Esposito, S, Falcini, F, Giordano, U, Maggio, MC, Mannarino, S, Marseglia, G, Martino, S, Marucci, G, Massaro, R, Pescosolido, C, Pietraforte, D, Pietrogrande, MC, Salice, P, Secinaro, A, Straface, E & Villani, A 2018, 'Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks', Italian Journal of Pediatrics, vol. 44, no. 1. https://doi.org/10.1186/s13052-018-0529-2
Marchesi, A. ; Tarissi De Jacobis, I. ; Rigante, D. ; Rimini, A. ; Malorni, W. ; Corsello, G. ; Bossi, G. ; Buonuomo, S. ; Cardinale, F. ; Cortis, E. ; De Benedetti, F. ; De Zorzi, A. ; Duse, M. ; Del Principe, D. ; Dellepiane, R.M. ; D'Isanto, L. ; El Hachem, M. ; Esposito, S. ; Falcini, F. ; Giordano, U. ; Maggio, M.C. ; Mannarino, S. ; Marseglia, G. ; Martino, S. ; Marucci, G. ; Massaro, R. ; Pescosolido, C. ; Pietraforte, D. ; Pietrogrande, M.C. ; Salice, P. ; Secinaro, A. ; Straface, E. ; Villani, A. / Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. In: Italian Journal of Pediatrics. 2018 ; Vol. 44, No. 1.
@article{bdb9791c774b484a9d07511c2e409f05,
title = "Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks",
abstract = "This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications. {\circledC} 2018 The Author(s).",
keywords = "anakinra, apixaban, canakinumab, clopidogrel, dabigatran, fondaparinux, hydroxymethylglutaryl coenzyme A reductase inhibitor, infliximab, low molecular weight heparin, methylprednisolone, prednisone, rivaroxaban, tissue plasminogen activator, warfarin, immunoglobulin, nonsteroid antiinflammatory agent, abdominal pain, adrenal cortex insufficiency, anaphylaxis, angioneurotic edema, arthralgia, atherosclerosis, bleeding, bradycardia, bronchospasm, cardiovascular disease, cardiovascular risk, cataract, chorioretinopathy, congestive heart failure, coronary artery aneurysm, coronary artery thrombosis, diabetes mellitus, diarrhea, digestive system perforation, disease classification, disease severity, dizziness, drug efficacy, drug mechanism, dysphagia, eosinophilia, erythema, face edema, fatigue, fitness, follow up, gastrointestinal hemorrhage, gastrointestinal symptom, glaucoma, hand edema, headache, heart arrhythmia, heart surgery, heart transplantation, human, hyperglycemia, hypersensitivity, hypertension, hypertransaminasemia, hypocalcemia, hypotension, hypothermia, hypovolemic shock, infection, influenza, information dissemination, intracranial hypertension, invasive procedure, lifestyle, liver failure, malaise, mucocutaneous lymph node syndrome, myalgia, myopathy, nausea, neutropenia, osteoporosis, pain, pancreatitis, pediatrician, Perthes disease, physician, plasmapheresis, pneumonia, practice guideline, pruritus, rash, Review, rhinitis, rhinopharyngitis, seizure, shock, sinusitis, skin bruising, thrombocytopenia, thrombosis, thrombotic thrombocytopenic purpura, treatment contraindication, treatment indication, upper respiratory tract infection, urticaria, vomiting, child, coronary artery disease, drug resistance, female, male, medical society, pediatrics, preschool child, risk assessment, severity of illness index, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Child, Child, Preschool, Coronary Artery Disease, Drug Resistance, Female, Follow-Up Studies, Humans, Immunoglobulins, Intravenous, Male, Mucocutaneous Lymph Node Syndrome, Pediatrics, Practice Guidelines as Topic, Risk Assessment, Severity of Illness Index, Societies, Medical",
author = "A. Marchesi and {Tarissi De Jacobis}, I. and D. Rigante and A. Rimini and W. Malorni and G. Corsello and G. Bossi and S. Buonuomo and F. Cardinale and E. Cortis and {De Benedetti}, F. and {De Zorzi}, A. and M. Duse and {Del Principe}, D. and R.M. Dellepiane and L. D'Isanto and {El Hachem}, M. and S. Esposito and F. Falcini and U. Giordano and M.C. Maggio and S. Mannarino and G. Marseglia and S. Martino and G. Marucci and R. Massaro and C. Pescosolido and D. Pietraforte and M.C. Pietrogrande and P. Salice and A. Secinaro and E. Straface and A. Villani",
note = "cited By 0",
year = "2018",
doi = "10.1186/s13052-018-0529-2",
language = "English",
volume = "44",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks

AU - Marchesi, A.

AU - Tarissi De Jacobis, I.

AU - Rigante, D.

AU - Rimini, A.

AU - Malorni, W.

AU - Corsello, G.

AU - Bossi, G.

AU - Buonuomo, S.

AU - Cardinale, F.

AU - Cortis, E.

AU - De Benedetti, F.

AU - De Zorzi, A.

AU - Duse, M.

AU - Del Principe, D.

AU - Dellepiane, R.M.

AU - D'Isanto, L.

AU - El Hachem, M.

AU - Esposito, S.

AU - Falcini, F.

AU - Giordano, U.

AU - Maggio, M.C.

AU - Mannarino, S.

AU - Marseglia, G.

AU - Martino, S.

AU - Marucci, G.

AU - Massaro, R.

AU - Pescosolido, C.

AU - Pietraforte, D.

AU - Pietrogrande, M.C.

AU - Salice, P.

AU - Secinaro, A.

AU - Straface, E.

AU - Villani, A.

N1 - cited By 0

PY - 2018

Y1 - 2018

N2 - This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications. © 2018 The Author(s).

AB - This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications. © 2018 The Author(s).

KW - anakinra

KW - apixaban

KW - canakinumab

KW - clopidogrel

KW - dabigatran

KW - fondaparinux

KW - hydroxymethylglutaryl coenzyme A reductase inhibitor

KW - infliximab

KW - low molecular weight heparin

KW - methylprednisolone

KW - prednisone

KW - rivaroxaban

KW - tissue plasminogen activator

KW - warfarin

KW - immunoglobulin

KW - nonsteroid antiinflammatory agent, abdominal pain

KW - adrenal cortex insufficiency

KW - anaphylaxis

KW - angioneurotic edema

KW - arthralgia

KW - atherosclerosis

KW - bleeding

KW - bradycardia

KW - bronchospasm

KW - cardiovascular disease

KW - cardiovascular risk

KW - cataract

KW - chorioretinopathy

KW - congestive heart failure

KW - coronary artery aneurysm

KW - coronary artery thrombosis

KW - diabetes mellitus

KW - diarrhea

KW - digestive system perforation

KW - disease classification

KW - disease severity

KW - dizziness

KW - drug efficacy

KW - drug mechanism

KW - dysphagia

KW - eosinophilia

KW - erythema

KW - face edema

KW - fatigue

KW - fitness

KW - follow up

KW - gastrointestinal hemorrhage

KW - gastrointestinal symptom

KW - glaucoma

KW - hand edema

KW - headache

KW - heart arrhythmia

KW - heart surgery

KW - heart transplantation

KW - human

KW - hyperglycemia

KW - hypersensitivity

KW - hypertension

KW - hypertransaminasemia

KW - hypocalcemia

KW - hypotension

KW - hypothermia

KW - hypovolemic shock

KW - infection

KW - influenza

KW - information dissemination

KW - intracranial hypertension

KW - invasive procedure

KW - lifestyle

KW - liver failure

KW - malaise

KW - mucocutaneous lymph node syndrome

KW - myalgia

KW - myopathy

KW - nausea

KW - neutropenia

KW - osteoporosis

KW - pain

KW - pancreatitis

KW - pediatrician

KW - Perthes disease

KW - physician

KW - plasmapheresis

KW - pneumonia

KW - practice guideline

KW - pruritus

KW - rash

KW - Review

KW - rhinitis

KW - rhinopharyngitis

KW - seizure

KW - shock

KW - sinusitis

KW - skin bruising

KW - thrombocytopenia

KW - thrombosis

KW - thrombotic thrombocytopenic purpura

KW - treatment contraindication

KW - treatment indication

KW - upper respiratory tract infection

KW - urticaria

KW - vomiting

KW - child

KW - coronary artery disease

KW - drug resistance

KW - female

KW - male

KW - medical society

KW - pediatrics

KW - preschool child

KW - risk assessment

KW - severity of illness index, Anti-Inflammatory Agents, Non-Steroidal

KW - Cardiovascular Diseases

KW - Child

KW - Child, Preschool

KW - Coronary Artery Disease

KW - Drug Resistance

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunoglobulins, Intravenous

KW - Male

KW - Mucocutaneous Lymph Node Syndrome

KW - Pediatrics

KW - Practice Guidelines as Topic

KW - Risk Assessment

KW - Severity of Illness Index

KW - Societies, Medical

U2 - 10.1186/s13052-018-0529-2

DO - 10.1186/s13052-018-0529-2

M3 - Article

VL - 44

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 1

ER -